EligibleTrials

Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment

Recruiting · NCT06534489 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ruijin Hospital

View the official record on ClinicalTrials.gov →
Lung cancer

Interventions studied

neoadjuvant immuno-chemotherapy and surgery

What this trial is about

Lung cancer is one of the most common malignant tumors worldwide and has the highest mortality rate among malignant tumors. In recent years, with the gradual development of therapeutic modalities such as targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, late tumor staging at the time of diagnosis often leaves patients with only pneumonectomy, which affects the prognosis with a higher rate of postoperative complications than lobectomy, poorer quality of life and the possible loss of the opportunity to continue adjuvant therapy. Our group proposes to conduct this single-arm prospective clinical study to investigate the feasibility, safety and prognosis of the conversion from pneumonectomy to lobectomy after neoadjuvant or induction therapy in patients with operable non-small cell lung cancer.

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.